AR and neoplasm: Among SDC, 81.1% were androgen receptor (AR)-positive, and 54.5% showed nuclear AR positivity in > 70% of tumor cells (ARhigh), whereas 45.5% showed nuclear AR positivity in ≤ 70% of tumor cells (ARlow).